Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
No evidence for CCVSI in relapsing-remitting multiple sclerosis patients with moderate disability.
Jacksonian seizure as the relapse symptom of multiple sclerosis.
Exercise in the community for people with minimal gait impairment due to MS: an assessor-blind randomized controlled trial.
Optic Nerve and its Arterial-Venous Vascularization: An Ultrasonologic Study in Multiple Sclerosis Patients and Healthy Controls.
Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.
Perceived changes and minimum clinically important difference of the Neurological Fatigue Index for multiple sclerosis (NFI-MS).
Amyloid PET imaging in multiple sclerosis: an (18)F-florbetaben study.
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
The role of epidemiology in MS research: Past successes, current challenges and future potential.
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.
Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
Determining the Presence of Reliable Change over Time in Multiple Sclerosis: Evidence from the PASAT, Adjusting-PSAT, and Stroop Test.
Risk of fractures in patients with multiple sclerosis: record-linkage study.
Signalling Pathways that Inhibit the Capacity of Precursor Cells for Myelin Repair.
Cerebrospinal fluid and urinary biomarkers in multiple sclerosis.
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome.
Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica.
Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients.
Neuroimmunological diseases and pregnancy.
Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system.
Expansion of Functional Human Mucosal-Associated Invariant T Cells via Reprogramming to Pluripotency and Redifferentiation.
Quality of life outcomes following surgery for patients with coexistent cervical stenosis and multiple sclerosis.
CNS demyelinating disorder with mixed features of neuromyelitis optica and multiple sclerosis in HIV-1 infection. Case report and literature review.
P2Y12 Receptor on the Verge of a Neuroinflammatory Breakdown.
Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.
Pages
« first
‹ previous
…
322
323
324
325
326
327
328
329
330
…
next ›
last »